Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2018-07, Vol.44 (7), p.991-996 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 996 |
|---|---|
| container_issue | 7 |
| container_start_page | 991 |
| container_title | European journal of surgical oncology |
| container_volume | 44 |
| creator | Nowacki, Maciej Alyami, Mohammad Villeneuve, Laurent Mercier, Frederic Hubner, Martin Willaert, Wouter Ceelen, Wim Reymond, Marc Pezet, Denis Arvieux, Catherine Khomyakov, Vladimir Lay, Laura Gianni, Sergio Zegarski, Wojciech Bakrin, Naoual Glehen, Olivier |
| description | Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings.
An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017.
Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6–8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC.
These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials. |
| doi_str_mv | 10.1016/j.ejso.2018.02.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2013105579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0748798318306747</els_id><sourcerecordid>2013105579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-8b86e6688baf0374fcf7037cce5473e4238a1707446b89a92e9ac09a24b48a483</originalsourceid><addsrcrecordid>eNp9kU2O1DAUhCMEYpqBC7BAXs4sEvyTxA5i02rxM9IgZgFry3FeiFuJ3dhOS-E0cxYuxBVwphvEipVlv69Kz1VZ9pLggmBSv94XsA-uoJiIAtMCk_JRtiEVozklFX-cbTAvRc4bwS6yZyHsMcYN483T7II2Fa1ZzTfZr0_zGI0GG8Ej7aaDhwFsMEdAE8TBdW5034xWI1K2QxH0YM83NS7BBOT6n_eCUZSEIcze_IAOGRu9OoA30VlYYfAuuBHpASYXB0jDBV3d3dxtd9crDP6YFjDOBpRUvfPTgwliZYMOKpo0DCg9o388tfLaWDep6NY1ogcVpwS-QVt78rRqtUxoWusICwpx7pbn2ZNejQFenM_L7Ov7d192H_Pbzx9udtvbXLOqjrloRQ11LUSresx42euep1NrqErOoKRMKMJTvmXdikY1FBqlcaNo2ZZClYJdZlcn34N332cIUU4maBhHZcHNQabSGMFVxZuE0hOqU0rBQy8P3kzKL5JguRYt93ItetUIialMRSfRq7P_3Ka0_kr-NJuAtycA0i-PBrwMOgWpoTMedJSdM__z_w0oy8Jl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013105579</pqid></control><display><type>article</type><title>Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nowacki, Maciej ; Alyami, Mohammad ; Villeneuve, Laurent ; Mercier, Frederic ; Hubner, Martin ; Willaert, Wouter ; Ceelen, Wim ; Reymond, Marc ; Pezet, Denis ; Arvieux, Catherine ; Khomyakov, Vladimir ; Lay, Laura ; Gianni, Sergio ; Zegarski, Wojciech ; Bakrin, Naoual ; Glehen, Olivier</creator><creatorcontrib>Nowacki, Maciej ; Alyami, Mohammad ; Villeneuve, Laurent ; Mercier, Frederic ; Hubner, Martin ; Willaert, Wouter ; Ceelen, Wim ; Reymond, Marc ; Pezet, Denis ; Arvieux, Catherine ; Khomyakov, Vladimir ; Lay, Laura ; Gianni, Sergio ; Zegarski, Wojciech ; Bakrin, Naoual ; Glehen, Olivier</creatorcontrib><description>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings.
An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017.
Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6–8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC.
These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2018.02.014</identifier><identifier>PMID: 29526367</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject><![CDATA[Administration, Inhalation ; Antineoplastic Agents - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Appendiceal Neoplasms - drug therapy ; Appendiceal Neoplasms - pathology ; Carcinoma - drug therapy ; Carcinoma - secondary ; Cisplatin - administration & dosage ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Doxorubicin - administration & dosage ; Female ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Neoplasms - pathology ; Humans ; Injections, Intraperitoneal - methods ; Innovation ; Male ; Mesothelioma - drug therapy ; Mitomycin - administration & dosage ; Multicenter study ; Organoplatinum Compounds - administration & dosage ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Peritoneal carcinomatosis ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - secondary ; PIPAC ; Practice Patterns, Physicians ; Practice survey ; Safety procedure ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Surveys and Questionnaires]]></subject><ispartof>European journal of surgical oncology, 2018-07, Vol.44 (7), p.991-996</ispartof><rights>2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology</rights><rights>Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-8b86e6688baf0374fcf7037cce5473e4238a1707446b89a92e9ac09a24b48a483</citedby><cites>FETCH-LOGICAL-c356t-8b86e6688baf0374fcf7037cce5473e4238a1707446b89a92e9ac09a24b48a483</cites><orcidid>0000-0002-8713-7821 ; 0000-0002-0885-6749 ; 0000-0002-0040-8511 ; 0000-0001-7692-4419 ; 0000-0001-8424-7198 ; 0000-0002-4521-8279 ; 0000-0002-2802-4974 ; 0000-0003-1448-0319</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0748798318306747$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29526367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nowacki, Maciej</creatorcontrib><creatorcontrib>Alyami, Mohammad</creatorcontrib><creatorcontrib>Villeneuve, Laurent</creatorcontrib><creatorcontrib>Mercier, Frederic</creatorcontrib><creatorcontrib>Hubner, Martin</creatorcontrib><creatorcontrib>Willaert, Wouter</creatorcontrib><creatorcontrib>Ceelen, Wim</creatorcontrib><creatorcontrib>Reymond, Marc</creatorcontrib><creatorcontrib>Pezet, Denis</creatorcontrib><creatorcontrib>Arvieux, Catherine</creatorcontrib><creatorcontrib>Khomyakov, Vladimir</creatorcontrib><creatorcontrib>Lay, Laura</creatorcontrib><creatorcontrib>Gianni, Sergio</creatorcontrib><creatorcontrib>Zegarski, Wojciech</creatorcontrib><creatorcontrib>Bakrin, Naoual</creatorcontrib><creatorcontrib>Glehen, Olivier</creatorcontrib><title>Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings.
An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017.
Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6–8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC.
These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.</description><subject>Administration, Inhalation</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Appendiceal Neoplasms - drug therapy</subject><subject>Appendiceal Neoplasms - pathology</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - secondary</subject><subject>Cisplatin - administration & dosage</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Neoplasms - pathology</subject><subject>Humans</subject><subject>Injections, Intraperitoneal - methods</subject><subject>Innovation</subject><subject>Male</subject><subject>Mesothelioma - drug therapy</subject><subject>Mitomycin - administration & dosage</subject><subject>Multicenter study</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Peritoneal carcinomatosis</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>PIPAC</subject><subject>Practice Patterns, Physicians</subject><subject>Practice survey</subject><subject>Safety procedure</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Surveys and Questionnaires</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2O1DAUhCMEYpqBC7BAXs4sEvyTxA5i02rxM9IgZgFry3FeiFuJ3dhOS-E0cxYuxBVwphvEipVlv69Kz1VZ9pLggmBSv94XsA-uoJiIAtMCk_JRtiEVozklFX-cbTAvRc4bwS6yZyHsMcYN483T7II2Fa1ZzTfZr0_zGI0GG8Ej7aaDhwFsMEdAE8TBdW5034xWI1K2QxH0YM83NS7BBOT6n_eCUZSEIcze_IAOGRu9OoA30VlYYfAuuBHpASYXB0jDBV3d3dxtd9crDP6YFjDOBpRUvfPTgwliZYMOKpo0DCg9o388tfLaWDep6NY1ogcVpwS-QVt78rRqtUxoWusICwpx7pbn2ZNejQFenM_L7Ov7d192H_Pbzx9udtvbXLOqjrloRQ11LUSresx42euep1NrqErOoKRMKMJTvmXdikY1FBqlcaNo2ZZClYJdZlcn34N332cIUU4maBhHZcHNQabSGMFVxZuE0hOqU0rBQy8P3kzKL5JguRYt93ItetUIialMRSfRq7P_3Ka0_kr-NJuAtycA0i-PBrwMOgWpoTMedJSdM__z_w0oy8Jl</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Nowacki, Maciej</creator><creator>Alyami, Mohammad</creator><creator>Villeneuve, Laurent</creator><creator>Mercier, Frederic</creator><creator>Hubner, Martin</creator><creator>Willaert, Wouter</creator><creator>Ceelen, Wim</creator><creator>Reymond, Marc</creator><creator>Pezet, Denis</creator><creator>Arvieux, Catherine</creator><creator>Khomyakov, Vladimir</creator><creator>Lay, Laura</creator><creator>Gianni, Sergio</creator><creator>Zegarski, Wojciech</creator><creator>Bakrin, Naoual</creator><creator>Glehen, Olivier</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8713-7821</orcidid><orcidid>https://orcid.org/0000-0002-0885-6749</orcidid><orcidid>https://orcid.org/0000-0002-0040-8511</orcidid><orcidid>https://orcid.org/0000-0001-7692-4419</orcidid><orcidid>https://orcid.org/0000-0001-8424-7198</orcidid><orcidid>https://orcid.org/0000-0002-4521-8279</orcidid><orcidid>https://orcid.org/0000-0002-2802-4974</orcidid><orcidid>https://orcid.org/0000-0003-1448-0319</orcidid></search><sort><creationdate>201807</creationdate><title>Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study</title><author>Nowacki, Maciej ; Alyami, Mohammad ; Villeneuve, Laurent ; Mercier, Frederic ; Hubner, Martin ; Willaert, Wouter ; Ceelen, Wim ; Reymond, Marc ; Pezet, Denis ; Arvieux, Catherine ; Khomyakov, Vladimir ; Lay, Laura ; Gianni, Sergio ; Zegarski, Wojciech ; Bakrin, Naoual ; Glehen, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-8b86e6688baf0374fcf7037cce5473e4238a1707446b89a92e9ac09a24b48a483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Inhalation</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Appendiceal Neoplasms - drug therapy</topic><topic>Appendiceal Neoplasms - pathology</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - secondary</topic><topic>Cisplatin - administration & dosage</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Neoplasms - pathology</topic><topic>Humans</topic><topic>Injections, Intraperitoneal - methods</topic><topic>Innovation</topic><topic>Male</topic><topic>Mesothelioma - drug therapy</topic><topic>Mitomycin - administration & dosage</topic><topic>Multicenter study</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Peritoneal carcinomatosis</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>PIPAC</topic><topic>Practice Patterns, Physicians</topic><topic>Practice survey</topic><topic>Safety procedure</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nowacki, Maciej</creatorcontrib><creatorcontrib>Alyami, Mohammad</creatorcontrib><creatorcontrib>Villeneuve, Laurent</creatorcontrib><creatorcontrib>Mercier, Frederic</creatorcontrib><creatorcontrib>Hubner, Martin</creatorcontrib><creatorcontrib>Willaert, Wouter</creatorcontrib><creatorcontrib>Ceelen, Wim</creatorcontrib><creatorcontrib>Reymond, Marc</creatorcontrib><creatorcontrib>Pezet, Denis</creatorcontrib><creatorcontrib>Arvieux, Catherine</creatorcontrib><creatorcontrib>Khomyakov, Vladimir</creatorcontrib><creatorcontrib>Lay, Laura</creatorcontrib><creatorcontrib>Gianni, Sergio</creatorcontrib><creatorcontrib>Zegarski, Wojciech</creatorcontrib><creatorcontrib>Bakrin, Naoual</creatorcontrib><creatorcontrib>Glehen, Olivier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nowacki, Maciej</au><au>Alyami, Mohammad</au><au>Villeneuve, Laurent</au><au>Mercier, Frederic</au><au>Hubner, Martin</au><au>Willaert, Wouter</au><au>Ceelen, Wim</au><au>Reymond, Marc</au><au>Pezet, Denis</au><au>Arvieux, Catherine</au><au>Khomyakov, Vladimir</au><au>Lay, Laura</au><au>Gianni, Sergio</au><au>Zegarski, Wojciech</au><au>Bakrin, Naoual</au><au>Glehen, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>44</volume><issue>7</issue><spage>991</spage><epage>996</epage><pages>991-996</pages><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings.
An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017.
Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6–8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC.
These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29526367</pmid><doi>10.1016/j.ejso.2018.02.014</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8713-7821</orcidid><orcidid>https://orcid.org/0000-0002-0885-6749</orcidid><orcidid>https://orcid.org/0000-0002-0040-8511</orcidid><orcidid>https://orcid.org/0000-0001-7692-4419</orcidid><orcidid>https://orcid.org/0000-0001-8424-7198</orcidid><orcidid>https://orcid.org/0000-0002-4521-8279</orcidid><orcidid>https://orcid.org/0000-0002-2802-4974</orcidid><orcidid>https://orcid.org/0000-0003-1448-0319</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2018-07, Vol.44 (7), p.991-996 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2013105579 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Inhalation Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Appendiceal Neoplasms - drug therapy Appendiceal Neoplasms - pathology Carcinoma - drug therapy Carcinoma - secondary Cisplatin - administration & dosage Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Doxorubicin - administration & dosage Female Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms - pathology Humans Injections, Intraperitoneal - methods Innovation Male Mesothelioma - drug therapy Mitomycin - administration & dosage Multicenter study Organoplatinum Compounds - administration & dosage Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Peritoneal carcinomatosis Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary PIPAC Practice Patterns, Physicians Practice survey Safety procedure Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Surveys and Questionnaires |
| title | Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T06%3A04%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20comprehensive%20methodological%20and%20technical%20analysis%20of%C2%A0832%20pressurized%20intraperitoneal%20aerosol%20chemotherapy%20(PIPAC)%20interventions%20performed%20in%20349%20patients%20for%20peritoneal%20carcinomatosis%20treatment:%20An%20international%20survey%20study&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Nowacki,%20Maciej&rft.date=2018-07&rft.volume=44&rft.issue=7&rft.spage=991&rft.epage=996&rft.pages=991-996&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2018.02.014&rft_dat=%3Cproquest_cross%3E2013105579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2013105579&rft_id=info:pmid/29526367&rft_els_id=S0748798318306747&rfr_iscdi=true |